Drugs / LAM561
LAM561
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03867123 | Dec 2018 → Jul 2020 | glioblastoma | Laminar Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04299191 | Sep 2020 → Oct 2026 expected | childhood malignant neoplasm, malignant glioma | Laminar Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01792310 | May 2013 → Sep 2016 | glioma | Laminar Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04250922 | Dec 2019 → Jan 2026 overdue | glioblastoma | Laminar Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAM561 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04299191 ↗ |
| Known as | 2-OHOA | “The first-in-class brain-penetrating synthetic hydroxylated lipid idroxioleic acid (2-OHOA; sodium 2-hydroxyoleate), activates sphingomyelin synthase expression and regulates...” PMID 37488446 ↗ Jul 2023 |
| Known as | idroxioleic acid | “The first-in-class brain-penetrating synthetic hydroxylated lipid idroxioleic acid (2-OHOA; sodium 2-hydroxyoleate), activates sphingomyelin synthase expression and regulates...” PMID 37488446 ↗ Jul 2023 |
| Known as | sodium 2-hydroxyoleate | “The first-in-class brain-penetrating synthetic hydroxylated lipid idroxioleic acid (2-OHOA; sodium 2-hydroxyoleate), activates sphingomyelin synthase expression and regulates...” PMID 37488446 ↗ Jul 2023 |
| Action | Activate | “activates sphingomyelin synthase expression” PMID 37488446 ↗ Jul 2023 |
| Modality | Small molecule | “The first-in-class brain-penetrating synthetic hydroxylated lipid idroxioleic acid” PMID 37488446 ↗ Jul 2023 |
| Route | Oral | “daily oral treatment with 2-OHOA monotherapy (BID/TID)” PMID 37488446 ↗ Jul 2023 |